How is the pharmaceutical industry reacting to the FDA’s surprising approval of a controversial Alzheimer’s drug, and what do they make of its $56,000 price tag?
This is the last episode in our weeklong series examining the potentially sweeping consequences this drug, known as aducanumab, could have on millions of patients’ lives and billions of dollars in health care spending.
Guest:
Luke Timmerman, Journalist/Founder, Timmerman Report
Explore the full series and additional resources: https://tradeoffs.org/aducanumab
Read a transcript of this episode: https://tradeoffs.org/2021/06/25/the-aducanumab-aftermath-the-industry/
Sign up for our weekly newsletter to see what research health policy experts are reading right now, plus recommendations from our staff: bit.ly/tradeoffsnewsletter
Support this type of journalism today, with a gift: https://tradeoffs.org/donate
Follow us on Twitter: https://twitter.com/tradeoffspod
Hosted on Acast. See acast.com/privacy for more information.
